The Applicability of Experimental Experience with the Total Artificial Heart to its Clinical Use

1992 ◽  
Vol 15 (5) ◽  
pp. 307-311 ◽  
Author(s):  
J. Vašků ◽  
P. Urbánek ◽  
M. Dostál ◽  
Jan Vašků

Long-term experiments with the total artificial heart (TAH) are a source of valuable knowledge for later clinical application. Our observations result from 66 long-term experiments on calves and one goat ranging from 30 to 314 days, which have shown the main possible complications in the early period (one month) and later in the experiment. Problems until the second month of pumping concern the clinical pendant of the TAH as a bridge for transplantation, i.e. surgical problems, blood coagulation disorders, infection etc. Later problems are high venous pressure or arterial hypertension, infection with septic thromboembolization, mineralization of the driving diaphragm, etc., and are more closely comparable to the conditions of permanent clinical use of the TAH. Faultless surgery, device function and the regimen of pumping are essential factors in every long-term experiment, just as in clinical application. Infection is a threat throughout any experiment, as in clinical cases. The TNS-BRNO-VII/clin/80 TAH has been implanted in six patients.

1992 ◽  
Vol 15 (2) ◽  
pp. 120-125 ◽  
Author(s):  
K. Cídl ◽  
M. Dostál ◽  
JAN Vašků ◽  
J. Nečas ◽  
P. Dobša'k

Changes in serum proteins, enzymes and isoenzymes of lactate dehydrogenase (LDH) were compared in long-term surviving calves with a total artificial heart without influencing their central venous pressure (CVP) and calves in which CVP was lowered by antihypertensive drugs administered from day 60 to the end of the experiment. Antihypertensive drugs helped keep CVP within physiological levels for longer and aided liver function as well as evidenced by the different values for the parameters studied in the two groups.


1980 ◽  
Vol 3 (1) ◽  
pp. 24-29
Author(s):  
H. Fukumasu ◽  
D.B. Olsen ◽  
J.H. Lawson ◽  
A. Mochizuki ◽  
N. Daitoh ◽  
...  

Two surgical techniques have been developed in our laboratory to deal with identifiable problems in long-term artificial heart experiments. A right thoracotomy is used to deal with problems such as extensive bleeding, which occur in the immediate postoperative stage of the experiment, while a left thoracotomy is used in cases in Which the original implantation is preceded by more than one week, since extensive adhesions complicate the right thoracotomy at that stage. Pulmonary problems have been eliminated as a primary cause of difficulties after reoperation, but infection remains a serious problem.


1991 ◽  
Vol 2 (3) ◽  
pp. 587-597
Author(s):  
Lawrence E. Barker

In the early 1800s, an awareness of potential ventricular failure stimulated interest in artificial heart replacement. In 1937 the first total artificial heart (TAH) was implanted into the chest of a dog by Russian physicians. The primary driving force for mechanical cardiac assistance developed from the necessity for circulatory assistance in order to perform corrective cardiac surgery. In 1953 the first successful closure of an atrial septal defect using extracorporeal circulation was performed. During the following decade the concept of using mechanical devices to assist the failing heart was aggressively pursued. This culminated in the first implant of a TAH in a human in 1969 as a bridge to transplant. Clinical implant of the TAH as a permanent device was performed in 1982 by researchers at the University of Utah. This patient lived for 112 days. Three successive permanent implants were performed in Louisville, Kentucky, with one patient surviving for 620 days. All of these permanent TAH patients suffered from device-related complications including bleeding, infection, and thromboembolic events. It became apparent that the present configuration of the TAH with its external drive lines and large air console was not ideal for long-term support. In 1985 the first implant of the Symbion J-7-100 TAH (Jarvik-7) as a bridge to transplant was performed. This patient was supported by the device for 9 days and was successfully transplanted and discharged home. Since 1985 more than 170 patients have been bridged using the Symbion J-7 TAH with more than 70% of these patients being successfully transplanted. The incidence of thromboembolic events has dramatically reduced with better understanding of anticoagulation requirements. Infection continues to be the greatest potential complication with these patients. In spite of this, the pneumatic TAH has proved to be an adequate bridge to transplant device


1993 ◽  
pp. 153-160 ◽  
Author(s):  
Motomi Shiono ◽  
Setsuo Takatani ◽  
Tatsuya Sasaki ◽  
Naoki Minato ◽  
Yukihiko Orime ◽  
...  

2016 ◽  
Vol 40 (12) ◽  
pp. 1137-1145 ◽  
Author(s):  
Jiri Wotke ◽  
Pavel Homolka ◽  
Jaromír Vasku ◽  
Petr Dobsak ◽  
Petra Palanova ◽  
...  

ASAIO Journal ◽  
1993 ◽  
Vol 39 (3) ◽  
pp. M373-M380 ◽  
Author(s):  
Eisuke Tatsumi ◽  
Pratap S. Khanwilkar ◽  
John R. Rowles ◽  
Bang Y. Chiang ◽  
Gregory L. Burns ◽  
...  

The Lancet ◽  
2015 ◽  
Vol 386 (10003) ◽  
pp. 1556-1563 ◽  
Author(s):  
Alain Carpentier ◽  
Christian Latrémouille ◽  
Bernard Cholley ◽  
David M Smadja ◽  
Jean-Christian Roussel ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document